ERBB2 and neoplasm: The PROTAC ARV-471, developed by Arvinas and Pfizer, is being evaluated in phase I/II trials in breast cancer as an oral ER degrader, and preclinical efforts to target HER2 have been effective in degrading HER2 to slow tumor growth (97).